IPREP Study #2: Evaluating Enhanced PrEP Packages for Young Female Sex Workers in Kisumu, Kenya
IPrEP, Study #2: Evaluating the Effectiveness, Feasibility and Acceptability of Enhanced Pre-exposure Prophylaxis (PrEP) Packages for Young Female Sex Workers in Kisumu, Kenya
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Kisumu, Kenya
- Tuungane Centre
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Report no previous diagnosis of HIV infection
- Report being a cisgender female or transgender female
- Report being between 18-24 years of age
- Report living or working in study area
- Report intention to stay in study area for 24 months
- Report exchange sex with men for goods, money, favors or other services in past 3 months
- Report no previous or recent (within the last 3 months) PrEP use
- Able to complete study procedures in English, Kiswahili or Dholuo
- Willingness to be randomized and adhere to study interventions according to eligibility, including PrEP
Exclusion Criteria:
- Ineligible for PrEP according to Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection in Kenya - 2018 Edition (National AIDS and STI Control Program, 2018)
- Unable to provide informed consent for study procedures
- Any medical, psychiatric, or social condition, or occupational or other responsibility that, in the judgment of the principle investigators, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
- Reports plan to leave area in the next 24 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Peer Support PS)
Participants randomized to the PS arm will be assigned a trained peer supporter (PSr) to enhance adherence to PrEP.
|
Participants randomized to the PS arm will be assigned a trained peer supporter.
The peer supporters (PSr) will establish rapport and build trusting relationships with participants in order to increase self-efficacy and motivation to adhere to the daily PrEP regimen and to engage in HIV prevention behaviors, in general.
The PSrs will assess for facilitators and barriers to PrEP adherence, conduct adherence counseling, and provide ongoing social and practical support (e.g.
tailored appointment reminders, accompanying participants to medical appointments, and providing skills building for effective relationships with study site providers).
PSrs will communicate with the participant on at least a weekly basis either in person or by phone and will track those who miss scheduled study visits.
Participants will be encouraged to contact their PSrs in case of questions or concerns.
For any clinical question, the peer supporter will direct the participant to the study nurse.
All participants will receive a one-month supply of daily oral PrEP (emtricitabine 200 mg/tenofovir 300 mg) [FTC/TDF] for the first month of enrollment.
|
|
EXPERIMENTAL: Reminders and Resource Transfer (RRT)
Participants randomized to the RRT arm will receive weekly SMS text messages and resource transfers to enhance adherence to PrEP.
|
All participants will receive a one-month supply of daily oral PrEP (emtricitabine 200 mg/tenofovir 300 mg) [FTC/TDF] for the first month of enrollment.
Participants who are randomized to the RRT arm will receive a discrete weekly SMS text (or voice message if participant is illiterate) to encourage healthy behaviors, study engagement and PrEP adherence.
Messages will be a general message that the participant has selected and will not have any information identifying the participant as part of the study or describing the purpose of the study.
An example text is "Remember to look after yourself today, See you tomorrow."
Participants will be requested to respond to the message with a brief answer.
Participants will be advised that each answered text counts as a point toward resource transfer that can be redeemed at scheduled study visits in the form of a small gift, such as cosmetics, personal care items, accessories, or airtime.The value of the reward increases with points.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PrEP Adherence between PS and RRT arms
Time Frame: 12 months
|
Proportion of participants with ARV in plasma at 12-month visit
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PrEP Adherence between PS and RRT arms, any visit
Time Frame: At all visits
|
Proportion of participants with detectable ARV in plasma at any visit
|
At all visits
|
|
PrEP Adherence between PS and RRT arms, self-report
Time Frame: At all visits
|
Proportion who report > 90% adherence by self-report
|
At all visits
|
|
PrEP adherence across PS and RRT arms
Time Frame: 18 and 24 months
|
Proportion of participants with ARV in plasma at 18- and 24- month visits
|
18 and 24 months
|
|
HIV risk behavior during PrEP use, propensity score
Time Frame: Baseline, 6, 12, 18, and 24 months
|
Comparison of sexual risk propensity score
|
Baseline, 6, 12, 18, and 24 months
|
|
HIV risk behavior during PrEP use, unprotected sex
Time Frame: Baseline, 6, 12, 18, and 24 months
|
Proportions of participants reporting unprotected vaginal or anal sex in the prior 30 days
|
Baseline, 6, 12, 18, and 24 months
|
|
Feasibility of PS and RRT interventions, intervention delivery
Time Frame: 24 months
|
Proportion of expected intervention sessions delivered
|
24 months
|
|
Feasibility of PS and RRT interventions, study visit retention
Time Frame: 24 months
|
Proportion of participants retained at each study visit
|
24 months
|
|
Completion of study visits between PS and RRT
Time Frame: 12, 18 and 24 months
|
Proportion who completed scheduled PrEP study visits in PS and RRT arms at 18 and 24 months compared to proportion who completed these study visits at 12 months
|
12, 18 and 24 months
|
|
Scaled perception of PrEP, PS and RRT
Time Frame: 24 months
|
Scaled perceptions of satisfaction with and utility of PS and RRT intervention components, PrEP, and clinical care
|
24 months
|
|
Safety of PrEP including social harms
Time Frame: 24 months
|
Discontinuation rates of PrEP due to an AE or drug toxicity and occurrence of social harms
|
24 months
|
|
Discontinuation of PrEP
Time Frame: 24 months
|
Discontinuation rates of PrEP due to situational changes, dislike of PrEP
|
24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Wafaa El-Sadr, MD, MPH, MPA, Columbia University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AAAS3722
- R01MH110051 (NIH)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.